First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 ...Middle East

New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) Treatment with...

Hence then, the article about first presentations of phase 3 data for bimekizumab across the full spectrum of axial spondyloarthritis to be shared at eular 2022 was published today ( Monday 23/05/2022 - 07:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 )

Also on site :

• General manager position restricted to only Saudis; Qiwa clarifies
• Why is ‘Deuce Bigalow’ rooting for Viktor Orban in Hungary?
• Lady Gaga Pauses Tokyo Concert to Condemn ICE and Support Americans ‘Who Are Being Mercilessly Targeted’: ‘We Need to Get Back to a Place of Safety’